Display options
Cite
Kohada Y, Kaiho Y, Takeda K, et al. Analysis of the circulating myeloid-derived suppressor cells during androgen deprivation therapy for prostate cancer. IJU Case Rep. 2021;4(6):367-370doi: 10.1002/iju5.12351.
Kohada, Y., Kaiho, Y., Takeda, K., Kuromoto, A., Ito, J., Teishima, J., Nakamura, Y., Kaifu, T., Nakamura, A., & Sato, M. (2021). Analysis of the circulating myeloid-derived suppressor cells during androgen deprivation therapy for prostate cancer. IJU case reports, 4(6), 367-370. https://doi.org/10.1002/iju5.12351
Kohada, Yuki, et al. "Analysis of the circulating myeloid-derived suppressor cells during androgen deprivation therapy for prostate cancer." IJU case reports vol. 4,6 (2021): 367-370. doi: https://doi.org/10.1002/iju5.12351
Kohada Y, Kaiho Y, Takeda K, Kuromoto A, Ito J, Teishima J, Nakamura Y, Kaifu T, Nakamura A, Sato M. Analysis of the circulating myeloid-derived suppressor cells during androgen deprivation therapy for prostate cancer. IJU Case Rep. 2021 Aug 01;4(6):367-370. doi: 10.1002/iju5.12351. eCollection 2021 Nov. PMID: 34755058; PMCID: PMC8560438.
Copy Download .nbib Format: NLM
Share it on

IJU Case Rep. 2021 Aug 01;4(6):367-370. doi: 10.1002/iju5.12351. eCollection 2021 Nov.

Analysis of the circulating myeloid-derived suppressor cells during androgen deprivation therapy for prostate cancer.

IJU case reports

Yuki Kohada, Yasuhiro Kaiho, Kazuya Takeda, Akito Kuromoto, Jun Ito, Jun Teishima, Yasuhiro Nakamura, Tomonori Kaifu, Akira Nakamura, Makoto Sato

Affiliations

  1. Division of Urology Faculty of Medicine Tohoku Medical and Pharmaceutical University Sendai Japan.
  2. Department of Urology Hiroshima University Graduate School of Biomedical Sciences Hiroshima Japan.
  3. Divisions of Immunology Faculty of Medicine Tohoku Medical and Pharmaceutical University Sendai Japan.
  4. Division of Pathology Faculty of Medicine Tohoku Medical and Pharmaceutical University Sendai Japan.

PMID: 34755058 PMCID: PMC8560438 DOI: 10.1002/iju5.12351

Abstract

INTRODUCTION: The present study showed the involvement of immunosuppressive myeloid-derived suppressor cells during the disease progression in a 69-year-old man with a prostate cancer.

CASE PRESENTATION: The patient with metastatic PC (cT4N1M1ab) was initially treated with primary androgen deprivation therapy for 5 months and then chemotherapy with docetaxel, but he expired at the 8th month. In order to investigate whether myeloid-derived suppressor cells are implicated in the cancer exacerbation during androgen deprivation therapy, we assessed the long-term changes in peripheral blood myeloid-derived suppressor cell fractions by using flow cytometry. While prostate-specific antigen levels decreased after androgen deprivation therapy, the population of each myeloid-derived suppressor cell subsets increased during disease deterioration.

CONCLUSION: Increase in myeloid-derived suppressor cells populations was correlated with prostate cancer progression.

© 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.

Keywords: androgen antagonists; myeloid‐derived suppressor cells; prognosis; prostate‐specific antigen; prostatic neoplasms

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. J Mol Med (Berl). 2012 Nov;90(11):1343-55 - PubMed
  2. Nat Rev Immunol. 2021 Aug;21(8):485-498 - PubMed
  3. Cancer Immunol Immunother. 2009 Jan;58(1):49-59 - PubMed
  4. J Leukoc Biol. 2020 Jan;107(1):43-56 - PubMed
  5. Cancer Immunol Res. 2020 Sep;8(9):1215-1227 - PubMed
  6. Nat Commun. 2016 Jul 06;7:12150 - PubMed
  7. N Engl J Med. 2010 Jul 29;363(5):411-22 - PubMed
  8. Clin Cancer Res. 2015 Aug 15;21(16):3771-82 - PubMed
  9. Cancer Res. 2007 Jan 1;67(1):425; author reply 426 - PubMed
  10. Cancer Immunol Immunother. 2014 Nov;63(11):1177-87 - PubMed
  11. Prostate. 2010 Mar 1;70(4):443-55 - PubMed
  12. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 - PubMed
  13. Int J Mol Sci. 2020 Jul 31;21(15): - PubMed
  14. J Natl Compr Canc Netw. 2016 Jan;14(1):19-30 - PubMed
  15. Nat Rev Immunol. 2012 Mar 22;12(4):253-68 - PubMed

Publication Types